In spite of failing to meet the primary end point, losmapimod exhibits potential for facioscapulohumeral muscular dystrophy.

Published Date: 26 May 2024

Phase 3 REACH trial evaluating losmapimod (Fulcrum Therapeutics) in patients with facioscapulohumeral muscular dystrophy is proceeding as planned, with topline data expected in Q4 2024.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.

2.

Researchers use AI to monitor side effects of chemotherapy and support families dealing with pediatric cancer.

3.

Study finds 20 minutes of mindful breathing can rapidly reduce intensity of cancer pain

4.

Report suggests a big improvement in lung cancer survival

5.

The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot